Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

Summary

The goal of this clinical trial is to test daratumumab in adult very high risk T-lineage lymphoblastic leukemia. The main question it aims to answer is wether the addition of daratumumab daratumumab to the national standard of care is able to increase the rate of MRD-negative patients after induction therapy. Participants will be treated with: • daratumumab in combination with a pediatric-inspired treatment scheme - as in the previous GIMEMA LAL1913 protocol.

Timeline

Start

2024-10-17

Primary completion

2029-10

Completion

2029-10

Drugs

Indications